Numerous immune and inflammatory markers—including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-CRP ratio, lymphocyte-to-monocyte ratio, and CRP-to-albumin ratio—have been shown to provide prognostic value in cancer patients [16–23]. This evidence concerns the gene ALB and cancer.